CLSA Announces Expansion of Board of Directors
|For Immediate Release
August 2, 2016
Will Zasadny, Associate Director, Communications
Senior executives from Allergan and Boehringer Ingelheim Fremont Inc. join CLSA board
SOUTH SAN FRANCISCO & SAN DIEGO, Calif., Aug. 2, 2016 – California Life Sciences Association (CLSA) today announced an expansion of its board of directors, adding two new members. Alex Kelly, Executive Vice President, Chief Communications Officer, Allergan and Jens H. Vogel, Ph.D., President & CEO, Boehringer Ingelheim Fremont Inc., have joined the CLSA board. CLSA is the nation’s largest statewide life sciences public policy advocacy and business solutions organization serving biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers across the state of California.
“We are delighted to further strengthen and broaden California Life Sciences Association’s board of directors with the addition of these new members. Alex Kelly and Jens Vogel bring diverse experience and perspectives to our association, and we are thrilled to have them join our team,” said Sara Radcliffe, President & CEO, California Life Sciences Association (CLSA). “By adding their expertise to our already impressive board, CLSA will continue its track record of helping grow and foster California’s world-leading life sciences sector.”
About Alex Kelly
Alex Kelly is Executive Vice President, Chief Communications Officer of Allergan. He was appointed to this position on April 20, 2015. Previously, he served as Senior Vice President, Chief Integration Officer, where he co-led the integration of Allergan and Actavis and led the integration of Forest Laboratories following its acquisition by Actavis. Prior to joining Actavis, Mr. Kelly was Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Laboratories. In that role, he led Forest’s corporate communications and investor relations programs. While at Forest, he led the integration of Aptalis Pharma following its acquisition in January 2014. Kelly also served as Vice President, Investor Relations at Bausch + Lomb. Kelly served as Senior Vice President, Investor Relations at Merck & Co., Inc. following the combination with Schering-Plough where he led the Global Communications and Investor Relations team. Kelly previously worked for Novartis as Executive Director, Investor Relations, after spending 14 years at Pharmacia. Kelly holds a Bachelor of Science in Pharmacy from Purdue University, where he graduated Cum Laude.
About Jens Vogel, Ph.D.
Jens H. Vogel, Ph.D. is President and CEO of Boehringer Ingelheim Fremont Inc. Jens has more than 20 years of experience in all aspects of biopharmaceutical development and manufacturing, through senior leadership roles in process & technology development, GMP manufacturing and global project leadership in the US, Germany and the UK. Prior, Jens served as Global Head of CMC Strategy & TechRA, covering CMC development & global regulatory strategy for the entire portfolio of innovative BI biologics, biosimilars and contract development & manufacturing projects. Prior to joining Boehringer Ingelheim Vogel was a member of Bayer’s Global Biologics Development Leadership Team. Jens contributed to the successful licensure and post launch support of multiple commercial biologics and more than 60 INDs/IMPDs, and was voted as one of the 100 most influential people in drug development and manufacture (The Medicine Maker Power List 2015). He holds a PhD in Biochemical Engineering from University of Braunschweig, Germany and completed executive education programs at Harvard Business School, University of Notre Dame, Mendoza College of Business and Caltech.
About California Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) is the leading voice for California’s life sciences sector. We work closely with industry, government, academia and other stakeholders to shape public policy, drive business solutions and grow California’s life sciences innovation ecosystem. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors and service providers. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged to create the state’s most influential life sciences advocacy and business leadership organization. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.
Associate Director, Communications of CLSA